Log In
person
Seagen Inc
SGEN
summarize
3 total product lines
calendar_month
Revenue as of 12/31/2022
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Targeted Cancer Therapies |
Branded Pharmaceuticals
These companies research, develop, and manufacture patented drugs.
|
1.71B | 86.96% |
| Targeted Cancer Therapies |
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
0.16B | 8.39% |
| Targeted Cancer Therapies |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
0.09B | 4.65% |
| keyboard_arrow_down |
Targeted Cancer Therapies
Branded Pharmaceuticals
|
1.71B | 86.96% |
| keyboard_arrow_right |
These companies research, develop, and manufacture patented drugs.
|
||
| keyboard_arrow_down |
Targeted Cancer Therapies
Pharmaceutical Patent Licensing
|
0.16B | 8.39% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||
| keyboard_arrow_down |
Targeted Cancer Therapies
Pre-Revenue Pharmaceuticals
|
0.09B | 4.65% |
| keyboard_arrow_right |
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||